LH is safe, reliable, and feasible for treatment of ICC patients aged 60 and older as it had better short-term clinical outcomes than OH and achieved long-term prognoses that were comparable to those of OH. The gene discussed is PLOD1; the disease is intrahepatic cholangiocarcinoma.